Literature DB >> 7685290

Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes.

M W Debono1, J Le Guern, T Canton, A Doble, L Pradier.   

Abstract

The effects of riluzole, an anticonvulsant and neuroprotective compound, on excitatory amino acid-evoked currents were studied in Xenopus laevis oocytes injected with mRNA from rat whole brain or cortex. Responses to kainic acid were blocked by riluzole (IC50 = 167 microM) as well as by the quinoxalinedione antagonists 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX: IC50 = 0.21 microM) and 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline (NBQX: IC50 = 0.043 microM). Riluzole was somewhat more potent at blocking responses to N-methyl-D-aspartic acid (NMDA: IC50 = 18.2 microM); the competitive NMDA receptor antagonist 2-amino-phosphonovaleric acid (2-APV) yielded an IC50 of 6.1 microM in this system. The inhibition by both riluzole and 2-APV was reversible and did not appear to be use dependent, unlike that of the channel blocker MK-801 ([+]-5-methyl-10,11-dihydro-5H-dibenzo-[a,d]cyclohepten-5,10-imine maleate). It was impossible to demonstrate an interaction of riluzole with any of the known ligand recognition sites on either the kainate or the NMDA receptor in radioligand binding studies. These results suggest a direct but non-competitive action of riluzole on ionotropic glutamate receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685290     DOI: 10.1016/0014-2999(93)90147-a

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  39 in total

1.  Preclinical evaluation of riluzole: assessments of ethanol self-administration and ethanol withdrawal symptoms.

Authors:  Joyce Besheer; Veronique Lepoutre; Clyde W Hodge
Journal:  Alcohol Clin Exp Res       Date:  2009-08       Impact factor: 3.455

2.  Targeting glial physiology and glutamate cycling in the treatment of depression.

Authors:  Gerald W Valentine; Gerard Sanacora
Journal:  Biochem Pharmacol       Date:  2009-04-17       Impact factor: 5.858

3.  New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1.

Authors:  Nichole Coleman; Brandon M Brown; Aida Oliván-Viguera; Vikrant Singh; Marilyn M Olmstead; Marta Sofia Valero; Ralf Köhler; Heike Wulff
Journal:  Mol Pharmacol       Date:  2014-06-23       Impact factor: 4.436

4.  Amyotrophic lateral sclerosis: from pathological mechanisms to patient care.

Authors:  G Scarlato
Journal:  J Neurol       Date:  1997-05       Impact factor: 4.849

5.  Increase of flexor reflex latency in patients with amyotrophic lateral sclerosis treated with riluzole.

Authors:  M W Riepe; G Klappenbach; A C Ludolph
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

6.  Longer-term open-label study of adjunctive riluzole in treatment-resistant depression.

Authors:  Hitoshi Sakurai; Christina Dording; Albert Yeung; Simmie Foster; Felipe Jain; Trina Chang; Nhi-Ha Trinh; Richard Bernard; Sean Boyden; Syed Z Iqbal; Samuel T Wilkinson; Sanjay J Mathew; David Mischoulon; Maurizio Fava; Cristina Cusin
Journal:  J Affect Disord       Date:  2019-07-02       Impact factor: 4.839

Review 7.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

8.  Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.

Authors:  Ananthakrishnan Sankaranarayanan; Girija Raman; Christoph Busch; Tim Schultz; Pavel I Zimin; Joachim Hoyer; Ralf Köhler; Heike Wulff
Journal:  Mol Pharmacol       Date:  2008-10-27       Impact factor: 4.436

Review 9.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

10.  Oral administration of memantine prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis.

Authors:  In-Soo Joo; Dong-Hoon Hwang; Jung-Im Seok; Sang-Kun Shin; Seung-Up Kim
Journal:  J Clin Neurol       Date:  2007-12-20       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.